Navigation Links
ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community
Date:8/6/2008

Company expands beyond core business of discovery and safety services to meet the evolving needs of the drug discovery and development community

BOSTON and CLEVELAND, Aug. 6 /PRNewswire/ -- ChanTest, the world-leading provider of validated ion channel-expressing cell lines and services for drug-discovery and development applications, will make a selection of its fully validated cell lines available to researchers through a new Web site: http://www.chantestchannels.com. ChanTest Founder and CEO Arthur ("Buzz") Brown announced the new business offering today at the Drug Discovery & Development Innovative Technologies conference in Boston. ChanTest's initial launch will be of nine cell lines that the company has validated on the major ion channel platforms, including manual patch clamp, PatchXpress(R), QPatch, IonWorks(R), Quattro(TM), and FLIPR-Tetra(R). Optimization on all platforms is in progress. According to Dr. Brown, the company will expand the number of cell lines available during 2008 to 64.

"As the preeminent ion channel company, our goal is to serve all the ion channel needs of pharmaceutical and biotech customers -- from early functional screens for profiling drug candidates or ranking within profiles during the drug-discovery process -- to a complete set of in vitro GLP service products for cardiac risk assessment," said Dr. Brown. "However, some companies prefer to maintain testing in house. For those customers, we're pleased to offer a new way that researchers can benefit from ChanTest's ion channel expertise and exhaustive study of the characteristics of our ion channel library -- by purchasing our validated cell lines. We want to ensure that all researchers have the best opportunity to identify ion channels as pharmaceutically relevant targets and accelerate work on providing new drugs to those targets."

The nine initial validated cell lines available currently include the following:

Channel: hERG hERG KvLQT1-MinK Kir2.1 Kv1.5

Cell Type: HEK293 CHO CHO HEK293 HEK293

Channel: Kv4.3 HCN4 Nav1.7 Kv1.3

Cell Type: HEK293 HEK293 CHO HEK293

ChanTest scientists were the first to prove hERG as the target for adverse cardiac events linked to non-cardiac drugs: Seldane (terfenadine), Propulsid (cisapride), and Nizoral (ketoconazole), and ChanTest pioneered the development of functional, cell-based ion channel testing as a means to predict cardiac side effects produced by non-cardiac drugs. Such testing is now a standard component of regulatory submissions prior to the approval of drugs for use in humans. ChanTest is committed to innovation, and is leading the next major advance in ion channel research and services with a $10 million program to develop the world's most extensive library or catalog of ion channels. ChanTest's expert electrophysiologists fully validate the ion channels for interrogation with functional, pharmacological, and biochemical assays.

About ChanTest

The preeminent ion channel services company, ChanTest serves its drug discovery and development customers with GLP safety and automated screening assays using its library of ion channel-expressing cell lines -- the most comprehensive in the world. Since its inception in 1998, ChanTest has tested some 20,000 compounds for approximately 400 global pharmaceutical and biotech companies -- helping them to achieve their drug safety and discovery goals. ChanTest works in partnership with customers to speed the drug-development process, save time and money, and ultimately -- to help make better, safer drugs. The company also offers a selection of its validated cell lines directly to customers for use in their internal research. Because of ChanTest's seminal role in this field, along with the company's uncompromising commitment to quality, ChanTest was named "most trusted fee-for-service provider" for ion channel screening in the HTStec Ion Channel Trends Survey for two years in a row. ChanTest is based in Cleveland, Ohio. For more information, please visit http://www.chantest.com.


'/>"/>
SOURCE ChanTest
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. ChanTest to Highlight the Worlds Largest Catalog of Ion Channel-Expressing Cell Lines and Discovery Services at Drug Discovery Technology, Booth 839
2. ChanTest Launches Redesigned Web Site
3. ChanTest to Highlight Most-Comprehensive Range of Ion Channel Profiling Screens and Consultation Services at 14th Annual SBS Conference, Booth 1104
4. ChanTest to Highlight Expanded Ion Channel Testing Services for Preclinical Safety at ToxExpo, Including the Worlds Largest Catalog of Validated Ion Channels, Booth 2504
5. Ingenuity Systems Launches Analysis Services
6. Monogram Biosciences Launches First Resistance Assay for HIV Integrase Inhibitors
7. iNutrition Launches New Fission Fruit Nutrition Bars
8. Shire Re-Launches ADHDSupport.com, a Virtual Road Map Providing Information, Tools and Practical Tips About Attention Deficit Hyperactivity Disorder (ADHD)
9. Mylan Launches First Generic Version of Antihypertensive Sular(R) ER in the United States
10. Ranbaxy Launches Omeprazole 40 mg Capsules
11. Sagent Pharmaceuticals Launches Ceftazidime for Injection, USP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Parallel 6 , ... announced today the Clinical Reach Virtual Patient Encounter CONSULT module which enables ... the physician and clinical trial team. , Using the CONSULT module, patients and physicians ...
(Date:6/27/2016)... June 27, 2016   Ginkgo Bioworks , a ... engineering, was today awarded as one of the ... the world,s most innovative companies. Ginkgo Bioworks is ... the real world in the nutrition, health and ... directly with customers including Fortune 500 companies to ...
(Date:6/24/2016)... Raleigh, NC (PRWEB) , ... June 24, 2016 , ... ... find the most commonly-identified miRNAs in people with peritoneal or pleural mesothelioma. Their findings ... here to read it now. , Diagnostic biomarkers are signposts in the blood, ...
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
Breaking Biology Technology:
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... subsidiary of Infosys (NYSE: INFY ), and Samsung ... global partnership that will provide end customers with a ... and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... for financial services, but it also plays a fundamental part ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
Breaking Biology News(10 mins):